Investors sent shares of the Bethlehem, Pennsylvania, company reeling 14.5% to $10.95 in pre-market trade.
For the quarter ended June 2018, OraSure Technologies posted earnings of $0.20 per share on revenue of $50.2 million. The consensus earnings estimate was $0.11 per share on revenue of $47.5 million. Revenue fell 3.4% compared with the same quarter a year ago.
Looking ahead, the company said it expects a first-quarter loss of $0.07 to $0.06 per share on revenue of $29.0 million to $30.5 million. The current consensus estimate is for earnings of $0.09 per share on revenue of $45.1 million for the quarter ending March 31, 2019.
OraSure Technologies makes oral fluid diagnostic products and specimen-collection devices in the US, Europe and internationally. The company makes the OraQuick Advance HIV test, which is widely used in hospitals and doctor's offices. OraSure also supplies oral fluid testing solutions for drugs-of-abuse testing.
Contact Uttara Choudhury at [email protected]